臺灣博碩士論文加值系統

本實驗以小鼠為模型探討微脂體包覆改變電腦斷層顯影劑於腎臟累積的動態變化。初步研究結果證實，隨著微脂體的包覆率提升，顯影劑於注射後各時間點在腎臟平均累積量相對呈現下降的趨勢，在30-300min期間最明顯達減少50-76%；且於注射後各時間點在腎臟達細胞毒性濃度的範圍大幅縮減，且集中於非腎病變好發的腎髓質區而集中於腎盂處。

The aim of the research is to investigate the influence of liposome encapsulation on the computed tomography (CT) contrast medium (CM) accumulation kinetics in kidney. The preliminary results indicated that encapsulation of CM in liposome could significantly reduce the mean accumulation concentration in kidney, especially between 30-300min for achieving 50-76% reduction; and also resulted in narrower harmful iodine dosage (> 18 mg/ml) distribution.

摘要……………………………………………………………………………………i
Abstract………………………………………………………………………………ii
Index…………………………………………………………………………………iii
Index of table…………………………………………………………………………iv
Index of figures………………………………………………………………………v
Chapter 1 Introduction………………………………………………………………1
1.1 Background…………………………………………………………………1
1.2 Purpose………………………………………………………………………4
Chapter 2 Literature survey……………………………………………………………8
2.1 Contrast medium-induced nephropathy……………………………………8
2.2 Classification of contrast medium……………………………………………8
2.3 Mechanisms of contrast medium-induced nephropathy……………………10
2.4 Clearance path of contrast medium…………………………………………12
2.5 Applications of liposome in CT……………………………………………14
Chapter 3 Materials and methods……………………………………………………15
3.1 Equipment…………………………………………………………………15
3.2 Materials and drugs…………………………………………………………15
3.3 Experimental methods………………………………………………………16
3.3.1 Formulation of contrast medium coated in liposomes………………16
3.3.2 Analysis of liposome particle size distribution (stability) …………17
3.4 CT image analysis…………………………………………………………18
3.5 MATLAB image analysis…………………………………………………19
Chapter 4 Results and discussion……………………………………………………22
4.1 Quantitative analysis about encapsulation rate of liposome to CT contrast medium by using X-ray images……………………………………………………23
4.2 Influence of liposomes-coated to contrast medium accumulated in the kidneys………………………………………………………………………………24
Chapter 5 Conclusion………………………………………………………………33
Referrence……………………………………………………………………………34

[1] H. Schoder, M. Gonen, Screening for cancer with PET and PET/CT: potential and limitations, Journal of Nuclear Medicine, 48 Suppl 1:4–18, 2007.
[2] T. G. Gleeson, S. Bulugahapitiya, Contrast-Induced Nephropathy, American Journal of Roentgenology, 183: 1673–1689, 2004.
[3] I. Goldenberg, S. Matetzky, Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies, Canadian Medical Association , 172: 1461–1471, 2005.
[4] L. Zhang, F. X. Gu, J. M. Chan, A. Z. Wang, R. S. Langer, O. C. Farokhzad. Nanoparticles in medicine: therapeutic applications and developments. "Clinical Pharmacology and Therapeutics 83, 761–69, 2008.
[5] M. E. R. O’Brien1, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D. G. Kieback, P. Tomczak, S. P. Ackland, F. Orlandi, L. Mellars, L. Alland, C. Tendler. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/DoxilR) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Annals of Oncology, 15, 440-449, 2004.
[6] A. N. Gordon, J. T. Fleagle, D. Guthrie, D. E. Parkin, M. E. Gore, A. J. Lacave. Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan. Journal of Oncology, 19, 3312-3322, 2001.
[7] O. Lyass, B. Uziely, R. Ben-Yosef, D. Tzemach, N. I. Heshing, M. Lotem, G. Brufman. A. Gabizon. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer, 89, 1037-1047, 2000.
[8] N. D. Santos, C. Allen, A.-M. Doppen, M. Anantha, K. A.K. Cox, R. C. Gallagher, G. Karlsson, K. Edwards, G. Kenner, L. Samuels, M. S. Webb, M. B. Ball, Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: Relating plasma circulation lifetimes to protein binding. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1768, 1367-137, 2007.
[9] A. A. Gabizon, Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Advanced Drug Delivery Reviews, 16, 285-294, 1995.
[10] Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003 2(5):347-60.
[11] Paoli EE, Kruse DE, Seo JW, Zhang H, Kheirolomoom A, Watson KD, Chiu P, Stahlberg H, Ferrara KW. An optical and microPET assessment of thermally-sensitive liposome biodistribution in the Met-1 tumor model: Importance of formulation. J Control Release. 2010; 143(1):13-22.
[12] I. Goldenberg, S. Matetzky. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ, 172, 1461-1471, 2005.
[13] P. B. Persson, P. Hansell, P. Liss, Pathophysiology of contrast medium–induced nephropathy. Kidney International, 68, 14–22, 2005.
[14] M. Tepel, P. Aspelin, N. Lameire. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation, 113, 1799-1806, 2006.
[15] R. Solomon. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int. 68, 2256-63, 2005.
[16] D. R. Martin, R. C. Semelka, A. Chapman, H. Peters, P. J. Finn, B. Kalb, H. Thomsen. Nephrogenic systemic fibrosis and contrast agent induced nephropathy: risks and benefits of contrast-enhanced MR and CT in renally impaired patients. J Magn Reson Imaging. 30, 1350-6, 2009.
[17] J. L. Abraham, C. Thakral. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. Eur J Radiol. 66, 200-7, 2008.
[18] M. A. Sieber, H. Pietsch, J. Walter, W. Haider, T. Frenzel, H.-J. Weinmann. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Investigative Radiology, 43, 65-75, 2008.
[19] R. Mehran, E. Nikolsky, Contrast-induced nephropathy: definition,epidemiology, and patients at risk, Kidney International Supplements, 69:511–515, 2006.
[20] C. Briguori, D. Tavano, A. Colombo, Contrast agent –associated nephrotoxicity, Progress in Cardiovascular Diseases, 445:493–503, 2006.
[21] P.B. Persson, P. Hansell, P. Liss, Pathophysiology of contrast medium–induced nephropathy, Kidney International , 68:14–22, 2005.
[22] M. Tepel, P. Aspelin, N. Lameire, Contrast-induced nephropathy:a clinical and evidence-based approach, Circulation , 113: 1799–1806, 2006.
[23]李惠娟，顯影劑引起之腎毒性，成醫藥誌第十九卷第五期，2009
[24] R. Solomon, The role of osmolality in the incidence of contrastinduced nephropathy: a systematic review of angiographic contrast media in high risk patients, Kidney International, 68:2256–2263, 2005.
[25] M. R. Rudnick, A. Kesselheim, S. Goldfarb, Contrast-induced nephropathy: how it develops, how to prevent it, Cleveland Clinic Journal of Medicine, 73:75–80, 2006.
[26] L. Paul, Iobitridol, Clinical Drug Investigation, 33:155–166, 2013.
[27] H. Fattahi, S. Laurent, F. Liu, N. Arsalani, E. L. Vander, R. N. Muller, Magnetoliposomes as multimodal contrast agents for molecular imaging and cancer nanotheragnostics, Nanomedicine (london england), 6:529–544, 2011.
[28] K. Na, S. A. Lee, S. H. Jung, B. C. Shin, Gadolinium-based cancer therapeutic liposomes for chemotherapeutics and diagnostics , Colloids and Surfaces B: Biointerfaces, 84:82–87, 2011.

[29] G. Romano, C. Briguori, C. Quintavalle, C. Zanca, N. V. Rivera, A. Colombo, G. Condorelli, Contrast agents and renal cell apoptosis, European Heart Journal, 20:2569–2576, 2008.
[30] M. Brezis, A. S. Rosen, Hypoxia of the renal medulla: its implications for disease, The New England Journal of Medicine, 332: 647–655, 1995.
[31] U. Veronesi, P. Boyle, A. Goldhirsch, R. Orecchia, G. Viale, Breast cancer, The Lancet, 365:1727–1741, 2005.
[32] W. A. Berg, L. Gutierrez, M. S. NessAiver, W. B. Carter, M. Bhargavan, R. S. Lewis, O. B. Ioffe, Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer, Radiology, 233:830– 849, 2004.
[33] A. Dencausse, X. Violas, H. Feldman, P. Havard, C. Chambon, Pharmacokinetic profile of iobitridol, Acta radiologica Supplementum, 400:25–34, 1996.
[34] J. M. Idee, C. Bault, H. Beaufils, C. Berthommier, J. Cambar, C. Corot, D. Doucet, C. Hartl, M. C. Jaudon, C. Jacquiaud, B. Lakhdar, M. Potier, R. santus, S. Torcherie, E. Vaudon, B. Bonnemain, Pharmacologic profile of iobitridol, a nonionic iodinated contrast medium, Acta radiologica Supplementum, 400:35–48, 1996.
[35] D. E. Rollins, C. D. Klaassen, Biliary excretion of drugs in man, Clinical Pharmacokinetics, 4:368–379, 1979.
[36] N. Lee, S.H. Choi, T. Hyeon, Nano-Sized CT Contrast Agents, Advanced Materials, 25:2641–2660, 2013.
[37] I. Bekersky, R. M. Fielding, D. E. Dressler, J. W. Lee, D. N. Buell, T. J. Walsh, Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans, Antimicrobial Agents and Chemotherapy, 46:828–33, 2002.
[38] L. Zhang, F. X. Gu, J. M. Chan, A. Z. Wang, R. S. Langer, O. C. Farokhzad, Nanoparticles in medicine: therapeutic applications and developments , Clinical Pharmacology & Therapeutics, 83:761–769, 2007.
[39] M. E. O'Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D. G. Kieback, P. Tomczak, S. P. Ackland, F. Orlandi, L. Mellars, L. Alland, C. Tendler, Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl(CAELYX/Doxil) versus conventional doxorubicin for first –line treatment of metastatic breast cancer, Annals of Oncology, 15: 440–449, 2004.
[40] A. N. Gordon, J. T. Fleagle, D. Guthrie, D. E. Parkin, M. E. Gore, A. J. Lacave, Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan, Journal of Clinical Oncology , 19:3312–3322, 2001.
[41] O. Lyass, B. Uziely, R. Ben-Yosef, D. Tzemach, N. I. Heshing, M. Lotem , G. Brufman, A. Gabizon, Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma, Cancer. , 89:1037–1047, 2000.
[42] K. B. Ghaghada, R. R. Colen, C. R. Hawley, N. Patel, S. Jr. Mukundan, Liposomal contrast agents in brain tumor imaging, Neuroimaging Clinicsof North America, 20:367–378, 2010.
[43] R. Saito, M. T. Krauze, J. R. Bringas, C. Noble, T. R. McKnight, P. Jackson , M. F. Wendland, C. Mamot , D. C. Drummond, D. B. Kirpotin, K. Hong, M. S. Berger, J. W. Park, K. S. Bankiewicz, Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain, Experimental Neurology, 196:381–389, 2005.
[44] K. B. Ghaghada, M. Ravoori, D. Sabapathy, J. Bankson, V. Kundra, A. Annapragada, New dual mode gadolinium nanoparticle contrast agent for magnetic resonance imaging, Academic Journal, 4: 1–7, 2009.
[45] W. J. Mulder, G. J. Strijkers, J. W. Habets, E. J. Bleeker, D. W. van der Schaft, G. Storm, G. A. Koning, A. W. Griffioen, K. Nicolay, MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle, The FASEB Journal, 19:2008–2010, 2005.
[46] C. T. Badea, K. K. Athreya, G. Espinosa, D. Clark, G. A. Paiman, Y. Li, D. G. Kirsch, J. G. Allan, A. Annapragada, K. B. Ghaghada, Computed tomography imaging of primary lung cancer in mice using a liposomal–iodinated contrast agent, Academic Journal, 7:1–7, 2012.
[47] A. Havron, S. E. Seltzer, M. A. Davis, P. Shulkin, Radiopaque Liposomes: a promising new contrast material for computed tomography of the spleen, Radiology, 140:507–511, 1981.
[48] P. J. Ryan, M. A. Davis, L. R. DeGaeta, B. Woda, D. L. Melchior, Liposomes loaded with contrast material for image enhancement in computed tomography–work in progress, Radiology, 152:759–762, 1984.
[49] E. E. Paoli, D. E. Kruse, J. W. Seo, H. Zhang, A. Kheirolomoom, K. D. Watson, P. Chiu, H. Stahlberg, K. W. Ferrara, An optical and microPET assessment of thermally-sensitive liposome biodistribution in the Met-1 tumor model: Importance of formulation, Journal of Controlled Release, 143:13–22, 2010.
[50] AVESTIN, Inc. and AVESTIN Europe GmbH http://www.avestin.com/
[51] D. J. George, Quasielastic light scattering, American Chemical Society, 62:1049–1057, 1990.
[52] D. J. George, Quasielastic light scattering, American Chemical Society, 62:1049–1057, 1990.
[53] Royal Philips http://www.philips.com.tw/